Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-02
2011-08-02
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S328000
Reexamination Certificate
active
07989417
ABSTRACT:
A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.
REFERENCES:
patent: 4885363 (1989-12-01), Tweedle
patent: 4988496 (1991-01-01), Srinvasan et al.
patent: 5068222 (1991-11-01), Camble et al.
patent: 5217955 (1993-06-01), Bogden et al.
patent: 5244883 (1993-09-01), Cai et al.
patent: 5369094 (1994-11-01), Schally et al.
patent: 5410018 (1995-04-01), Spindel et al.
patent: 5428018 (1995-06-01), Edwards et al.
patent: 5428019 (1995-06-01), Edwards et al.
patent: 5534497 (1996-07-01), Verbruggen
patent: 5620955 (1997-04-01), Knight et al.
patent: 5620959 (1997-04-01), Leban et al.
patent: 5646272 (1997-07-01), Kramer et al.
patent: 5686410 (1997-11-01), Albert et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5834433 (1998-11-01), Krstenansky
patent: 5965695 (1999-10-01), Simon et al.
patent: 6075121 (2000-06-01), Simon et al.
patent: 6153729 (2000-11-01), Stein et al.
patent: 6200546 (2001-03-01), Hoffman et al.
patent: 6461588 (2002-10-01), Anelli et al.
patent: 2003/0224998 (2003-12-01), Reubi et al.
patent: WO91/01144 (1991-02-01), None
patent: WO96/03427 (1996-02-01), None
patent: WO 98/02192 (1998-01-01), None
patent: 99/55376 (1999-11-01), None
patent: 01/09163 (2001-02-01), None
patent: PCT/EP01/01971 (2001-02-01), None
patent: 01/64708 (2001-09-01), None
patent: WO 01/64708 (2001-09-01), None
patent: WO 01/76531 (2001-10-01), None
patent: 02/087597 (2002-11-01), None
Betebenner et al. “Hepatobiliary delivery of polyaminopolycarboxylate chelates: synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate” Bioconjugate Chemistry vol. 2, No. 2, 1991 pp. 117-123.
Supplementary European Search Report for European Application No. 03808615, May 2, 2007.
Giblin et al. (1998), Proc. Natl. Aca. Sci., USA, vol. 95, pp. 12814-12818.
Walsh et al., Western Journal of Medicine, vol. 155, pp. 152-163, 1991.
Heppeler et al., Receptor Targeting for Tumor Localization and Therapy with Radiopeptides. Current Medicinal Chemistry 2000, 7:971-994.
Sethi et al., Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo, Cancer Res. May 1, 1992;52(9 Suppl):2737s-2742s.
Halmos, T., Wittliff, J.L., and Schally, A.V., Characterization of bombesin/gastrin releasing peptide receptors on human breast cancer and their Relationship to steroid receptor expression, Cancer Research 55:280-287, 1995.
Kelly, K., Kane, M.A., and Bunn, P.A., “Growth factors in lung cancer: Possible etiologic role and clinical target”, Medical and Pediatric Oncology 19:449-458, 1991.
Jensen, R.T., Mrozinski, J.E., and Coy, D.H., “Bombesin receptor antagonists: Different classes and cellular basis of action”, Recent Results in Cancer Research 129:87-113, 1993.
Reile, H., Armatis, P.E., and Schally, A.V., Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells, Prostate, Jul. 1994;25(1):29-38.
Schutte, J., and Seeber, S., “Bombesin antagonists: Experimental and clinical results”, Recent Results in Cancer Research 129:115-129, 1993.
Walsh, J.H., Karnes, W.E., Cuttitta, F., and Walker, A., “Autocrine growth factors and solid tumor malignancy”, Western Journal of Medicine 155: 152-163, 1991.
Leban, et al., Potent gastrin-releasing peptide (GRP) antagonists derived from GRP (19-27) with a C-terminal DPro psi [CH2NH]Phe-NH2 and N-terminal aromatic residues, J Med Chem. Feb. 18, 1994;37(4):439-45.
Li, et al.; In-Vivo and In-Vitro Characterization of a Rh-105-Tetrathiamacrocycle Conjugate of a Bombesin Analogue, Proceedings of the 43rd Annual Meeting, vol. 37, No. 5, May 1996 Supplement, p. 61.
Zhu, et al.; Binding, internalization, and processing of bombesin by rat pancreatic acini, Bombesin Binding and Internalization, 1991, pp. G57-G64.
Moody, et al.; BW1023U90: A new GRP Receptor Antagonist for Small-Cell Lung Cancer Cells, Peptides vol. 17, No. 8, pp. 1337-1343, 1996.
Moody, et al.; A GRP Receptor Antagonist Which Inhibits Small-Cell Lung Cancer Growth; Life Sciences, vol. 56, No. 7, pp. 521-529, 1995.
Seifert, et al.; No Carrier Added Preparations of ′3+1′ Mixed-ligand 99mTc Complexes, Appl. Radiat. Isot. vol. 49, Nos. 1-2, pp. 5-11, 1998.
Smith, et al.; In Vivo and In Vitro Characterization of Novel Water-Soluble Dithio-Bisphosphine 99mTc Complexes, Nuclear Medicine & Biology, vol. 24, pp. 685-691, 1977.
Coy et al, “Short Chain Pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic Acinar and swiss 3T3 cells display strong Antimitotic activity” J. Biol. Chem., vol. 264, No. 25, pp. 14691-14697, 1989.
Thomas et al., Antitumoral Activity of Bombesin Analogues on Small Cell Lung Cancer Xenografts: Relationship with Bombesin Receptor Expression, Cancer Res. Sep. 15, 1992;52(18):4872-7.
Radulovic et al., Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice, Acta Oncol. 1994;33(6):693-701.
Qin, et al., Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro, Cancer Res. Feb. 15, 1994;54(4):1035-41.
Qin, et al., Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP, Int J Cancer. Oct. 9, 1995;63(2):257-62.
Cai et al., Potent Bombesin antagonists with C-Terminal Leu-(CH2-N)-Tac-NH2 or its Derivatives, (1994) Proc. Natl. Acad. Sci., 91:12664-12668.
Radulovic, et al., Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi, Int J Pept Protein Res. Dec. 1991;38(6):593-600.
Staley, et al., [Des-Met14]bombesin analogues function as small cell lung cancer bombesin receptor antagonists, Peptides. Jan.-Feb. 1991;12(1):145-9.
Wang et al., Desmethionine alkylamide bombesin analogues: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells, Biochemistry. Jan. 23, 1990;29(3):616-22.
Wang, Knezetic, Schally, Pour, Adrian; Bombesin May Stimulate Proliferation of Human Pancreatic Cancer Cells Through an Autocrine Pathway, Int. J. Cancer: 68, 528-534 (1996).
Yano, Pinski, Groot, Schally, Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines, Cancer Res. Aug. 15, 1992;52(16):4545-7.
Kane, Auguayo, Portanova, Ross, Holley, Kelly, Miller, Isolation of the bombesin/gastrin-releasing peptide receptor from human small cell lung carcinoma NCI-H345 cells, J Biol Chem. May 25, 1991;266(15):9486-93.
Schuller, Receptor-mediated mitogenic signals and lung cancer, Cancer Cells. Dec. 1991;3(12):496-503.
Halmos et al., Characterization of bombesin/gastrin-releasing peptide receptors in human breast
De Haën Christoph
Nunn Adrian D.
Swenson Rolf E.
Bracco Imaging S.p.A.
Kramer Levin Naftalis & Frankel LLP
Tate Christopher R.
Teller Roy
LandOfFree
Linkers for radiopharmaceutical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Linkers for radiopharmaceutical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Linkers for radiopharmaceutical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659172